I. Introduction
"l'hc withdrawal or abstinence syndrome associated with the discontinuation of chronic opiate drug use is quite different to that associated with the discontinuation of chronic psychomotor stimulant drug use. For example, the former includes a variety of overt neumlogic and vegetative signs, as well as subjective symptoms of distress, whereas the latter is more subtle, consisting primarily of subjective symptoms [7] . However, some of the subjective symptoms associated with opiate and psychomotor stimulant withdrawal are similar, including anxiety, depression, dysphoria and drug craving. The similarity of the subjective symptoms of withdrawal across drug classes has led some investigators to suggest they may have a common neurobiological substrate [2, 16, 18] .
Mesotelencephalic dopamine (DA) systems arc known to play an important role in mediating the positive reinforcing effects of a variety of drugs of abuse [21] , and it has been suggested that an increase in DA ncurotransmission is responsible for the subjective pleasurable aspects of drug action (see [14] for review and an alternative hypothesis). Given this vicw. it is reasonable to hypothesize that at decrease in DA neurotransmission may be responsible for some of the unpleasant subjective symptoms associated with drug withdrawal syndromes [2, 16, 18] . Consistent with this idea, a decrease in the extracellular concentration ol DA in the ventral striatum, as estimated by microdialysis, is reported to accompany the withdrawal syndromes associated with the abrupt discontinuation ot chronic treatment with ethanol [5, 16, 17] . morphine [I,2,13,16], amphetamine [16] or cocaine [6,1(), 16, 20] . Some researchers, on the other hand, have reported that amphetamine withdrawal is not accompanied by a decrease in the cxtracellular concentration of DA in the ventral striatum [4, 19, 22] . The purpose of the two experiments reported hcrc, therefore, was to reevaluate the relationship between changes in cxtraccllular DA in the ventral-medial striatum, as estimated by in vivo microdialysis sampling, and the withdrawal syndromes associated with morphine vs. amphetamine abstinence.
Methods

Experiment 1: Withdrawal from morphine Subjects
Thirty male Sprague-Dawley rats, initially weighing 250-300 g, were housed individually in stainless steel hanging cages. The animals had frec access to food and water and were maintained on a 14:11) h light/dark c3'cle.
Surgery
Each rat was anesthetized with sodium pentobarbital, and standard stereotaxic techniques were used to place a 21 gauge thin-wall stainless steel guide cannula on the surface of the dura, above the ventral-medial striatum (nucleus accumbens; [12] ). This was fixed in place with jeweler's screws and cranioplastic cement. The rats were allowed to recover from surgery for at least 4 days before beginning drug treatments.
Drug pretreatment and dialysis procedures
The animals were given daily injections of morphine sulfate (Mallinckrodt) or 0.9% saline for 15 days according to a regimen adapted from Acquas et al. [1] . The animals were injected subcutaneously twice per day (approximately 12 h apart) and the dose of morphine was escalated as follows: day 1, 10 mg/kg (weight of the salt); day 2, 20 mg/kg; day 3-4, 40 mg/kg; day 5-6, 60 mg/kg; day 7-8, 8(I mg/kg; day 9-10, 100 mg/kg; day 11-12, 120 mg/kg; day 13-15, 140 mg/kg.
On day 15 the animals were transferred from their home cages to the dialysis test chambers. Approximately I h later they received one additional injection, and 2 h later each rat was briefly restrained manually while a dialysis probe (see below) was lowered into the ventral-medial striatum via the previously implanted guide cannula. The probes were perfused with a sterile salt solution containing 145 mM NaCI, 2.7 mM KCI, 1.2 mM CaCI,, 1.0 mM MgCI 2 and 0.2 mM ascorbic acid, pll 7.3 [8] , at a flow rate of 1.5 /zl/min during probe implantation. The perfusion rate was then decreased to 0.3 /~l/min, and the animals were left undisturbed overnight in the test chamber.
Approximately 22 h after the last injection of morphine or saline, the flow rate through the probes was increased to 1.5 p.l/min. After a minimum stabilization period of 1 h, at least three 30-rain samples of dialysate were collected. After this, all of the morphine-pretreated (dependent) rats were given an injection of 60 mg/kg of morphine (s.c.), half of the saline-pretreated rats received 10 mg/kg of morphine (s.c.), and the remaining saline-pretreated rats received 0.9% saline (s.c.). A dose of 60 mg/kg of morphine was used in morphinedependent rats because in pilot studies we determined this was sufficient to alleviate withdrawal symptoms for over 2 h. Following the injection of morphine or saline three more 30-min samples of dialysate were collected. Next, all of the saline-pretreated rats were given an injection of 1 mg/kg of naloxone (i.p.), half of the morphine-dependent rats received 1 mg/kg of naloxone (i.p.), and the remaining morphine-dependent rats received no injection. Following this, four additional 30-min samples of dialysate were collected. Thus, there were four experimental groups: (1) morphine-dependent rats given morphine only; (2) morphine-dependent rats given morphine followed by naloxone; (3) saline-pretreated rats given morphine followed by naloxone; and (4) saline-pretreated rats given saline fl)llowed by naloxone. the ventral-medial striatum. All probes were tested tor recovery of DA in vitro prior to use, and there were no group differences in recovery. The average recovery value for DA was 21.27+0.43%.. Dopamine in dialysate was separated by HPLC and analyzed using electrochemical detection, as described previously [15] .
Behat,ior
Behavior wes monitored continuously throughout the 5-h dialysis test session, and symptoms of withdrawal were scored using scales similar to those described by Blasig et al. [3] . Each incident of the following behaviors was scored as one point: teeth chattering, wet-dog shaking, jumping, and abdominal stretching. One continuous episode of teeth-chattering was scored as one point and duration was not recorded. In addition, the presence or absence of the following symptoms was recorded every 15 min, and one point was scored if the symptom was present: diarrhea, ptosis, lacrimation and vocalization upon a light touch to the back. The total "withdrawal score' for each animal was summed across 30-min intervals, corresponding to the 30-rain dialysis sample intervals. Thus, a high score on this scale
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Dialysa probes
Concentric dialysis probes similar to those described by Robinson and (;amp [15] were constructed from regenerated cellulose hollow dialysis fiber. One mm of stainless steel cannula and 7 mm of dialysis fiber extended below the skull surface. The dorsal 4 mm of fiber was coated with cyanoacrylate, leaving 3 mm of effective membrane in 'q';
reflects tile trequenl OCClFrrence ot the hcha,.it~rs and s~,.mpton~s s:.F nl pied.
Follm~.ing the dialysis test session, cach animal was given a lethal dose ol stadium pentoharbital, and then perfused through the heart v, ith (I.tJrl saliFlC and il l()'r.; lormalm solution. The brain was remuv~:d. Inlzcn and sectioned. The sections were stained with ('resyl violet and examined to determine the exact probe placement. Only those animals with probes that had at least 75',; of the dialysis, surlae¢ within the ventral-medial striatum (primarily nucleus accumbens) v.erc used m the cxperirnent. The neurochcmical data from lour animals were excluded due tO incorrect prohe placenlents or broken probes, hut the hehavioral data h'om these animals were LFscd.
I:.qwriment 2: Withdrawal fi'om amphetamine .S'uhject,~ and ~ur,w'rv
Forty-three male Sprague-Dawle~, rats, initially weighiug 251) 3()U g. v, crc housed, and prepared with a guide cannula, as described in I{xpt. I.
Drug treatment and dialysis procedures
"]'he rafts wcrc prctrcatcd with two injections per day. 9-12 h apart, of t~-amphctaminc sulfate (1.5 mg/kg, i.p., weight of the salt) or 11.9'~ saline fi~r 14 consecutive days, as described by Rossetti et al.
[16]. ()n day 15, the animals received only one injection of amphetamine or saline in the morning. Approximately 2 h later, half of the amphetamine-pretreated and halt of the saline-pretreated animals were given chloral hydrate (i.p.. 40{I mg/kg) in three separate injections 1(1 min apart [16}. While these animals were anesthetized, a dialysis probe (sec above) was lowered into the ventral-medial qriatum via the previously implanted guide cannula, and the rats were then placed into the dialysis test chambers. The remaining rats were unl.~ briefly restrained (manualb') while the probe was lowered. During the implantation procedure the probes were perfused with the s,|mc sail solution as described in Expt. represent samples collected following naloxone <~lr saline) admmi,,-tration. Triangles represent samples ohtaincd h'ln11 saline-pretreated rats and circles represent samples obtained from1 nlorphinc-pretreated (dependent) rats. All salinc-pretrealed rats (n = 13l and all morphine-dependent rats {n-13)',,.ere pooled to calculate the meal~ basal values (intc~.'als BI--B3). Following the collection ~1 three basal samples, the s~,line-pretreated group v, as divided into tv.o subgroups. The larger triangles represent those rats thal reccixed Ill mg/kg morphine (n 8) and thc smaller triangles represent thos,: ruts that received saline (n = 5). Morphine <t~r salincl was gi'.en al the time indicated by the arrowhead labelled "M'. After morphine ~n saline administration, three additi,mal 3it-rain samples of dialysal~: were collected (inten,.als MI M3). After this. hoth subgroups ol saline-pretreated rats received 1.0 mg/kg naloxonc, at the lime indicated by the arrowhead labelled "N'. and hmr additional sample, of dialysatc were collected. The Hack triangles represent, thercfuru. saline-pretreated rats thal received morphine followed hy ilalox 
Results
Experiment 1." Withdrawal from morphine
Histology Fig. 1 (left) illustrates the location of the dialysis probes in the ventral-medial striatum of animals used in this experiment.
Dialysis
Fig . 2 shows the mean (+ S.E.M.) concentration of DA in dialysate for each group during the entire dialysis test session. Fig. 2 shows that there was a significant decrease in the basal concentration of DA obtained from animals undergoing spontaneous withdrawal from morphine (intervals B1-B3). Indeed, the basal concentration of DA in morphine-dependent animals (0.43 + 0.05 pg/gl) was approximately half that in saline-pretreated animals (0.81 + 0.10 pg/p.l; see the figure legends for presentation of statistical analyses).
In saline-prctreated animals, morphine administration produced a significant increase in DA concentrations (intervals MI-M3), which was reversed transiently by subsequent naloxone administration (intervals N I-N2). Naloxone alone had no effect in control animals (Fig. 2) . In morphine-dependent animals the administration of morphine also produced a significant increasc in DA concentrations (see Fig. 2 ), which was reversed by a naloxonc challenge (intervals N1-N4). It is important to note, however, that following the naloxone challenge DA concentrations in morphine-dependent animals did not return to the depressed levels seen during spontaneous withdrawal, and in fact, during intervals N1-N4 DA concentrations in morphine-dependent animals did not differ significantly from those in saline control animals.
Beharior
Fig . 3 shows the average behavioral withdrawal ratings over the entire dialysis test session. Also, the average concentration of DA in dialysate is replotted from Fig. 1 for morphine-dependent animals given naloxone, and for saline control animals, to facilitate comparison of the behavioral and neurochcmical data.
As expected, morphine-dependent animals exhibited spontaneous symptoms of withdrawal 1 day after their last pretreatment injection of morphine (intervals B1-B3; Fig. 3 ). Morphine administration eliminated the symptoms of withdrawal in morphine-dependent animals (i.e., there were no group differences in withdrawal ratings during intervals M1-M3). Naloxone administration reinstated withdrawal symptoms in morphine-dependent animals, but had no effect on saline control animals (intervals N1-N2). Naloxone-precipitatcd withdrawal was maximal for about 1 h after naloxone administration, but by the second hour (intervals N3-N4) withdrawal symptoms had dissipated. By the second hour after naloxone administration morphine-dependent animals did not differ from control, and also showed significantly fewer symptoms of withdrawal than at the beginning of the test session (i.e., intervals BI-B3 vs. N3-N4). Morphine-dependent animals given morphine followed by saline (instead of naioxone) did not show symptoms of withdrawal during intervals N l-N4 (data not shown).
A direct comparison of withdrawal symptoms and extracellular DA over the entire test session is especially interesting (Fig. 3) . Spontaneous withdrawal was associated with a decrease in the concentration of DA in dialysate, and the alleviation of withdrawal symptoms by morphine replacement was associated with an increase in DA concentrations. Reinstatement of withdrawal symptoms by naloxone was accompanied by a decrease in DA concentrations. These results suggest a correlation between the concentration of DA in dialysate and the presence or absence of withdrawal symptoms. Fig. 3 also shows, however, clear dissocia- (1) Morphine-dependent animals showed spontaneous symptoms of withdrawal (mean ratings over intervals B1-B3 for saline-pretreated vs. morphine-pretreated rats, MannWhitney U test, U= 0.0, P < 0.0001). (2)Morphine administration significantly reduced withdrawal symptoms in morphine-dependent rats (mean ratings for intervals BI-B3 vs. M1-M3, paired sign test, P < 0.0001), and for intervals MI-M3 morphine-dependent rats did not differ from control (Mann-Whitney U test). (3) Naloxone increased withdrawal symptoms in morphine-dependent rats for approximately 1 h (ratings for intervals Ml-M3 vs. N1-N2, paired sign test, P = 0.002), but by the second hour after naloxone administration symptoms of withdrawal dissipated (ratings for intervals M1-M3 vs. N3-N4, paired sign test, P = 0.34). 
Discussion
Symptoms of spontaneous morphine withdrawal were clearly evident I day following discontinuation of chronic morphine treatment. Consistent with previous reports [I,2,16] (c.f. [13] ). spontancous morphine withdrawal was associated with a ~ignilicam decrease in tlw cxtracelluiar eonccntralJon of l)i\ in Iht.' vcnllal ,4tii,i tun1, ;.is estimated by in rive mierodi;llysis. Morphine rephicemeni alleviated withdra~val ~,$.ml)iolns, ;lnd increased the extraccllular elmccnlralhul o1 I)i\. l'hcsc data are consistent wiih the hypothesi~ thai a deprt:,,-sion in extracelhilar DA may eontributc to some of the symptonls of nlorphJnt: w.ithdraw,il [2. lfl, 1~41.
On the other hand, lhe cxpcrinwnt involving naloxone-precipitated withdrawal shoves Ih;ii lhc synlplo111', of morphine withdrawal can be dissociated lrom the cxtracelluhtr concentration of DA. at lcasl in the ventral-medial strJatum, suggesting thai the correlation described above may not be Jndic;llivc of a direct causal rehitionship. Two examples of ;i dissociation between morphine withdrawal symptoms and cxtracclhihir I)A were found. First. although naloxonc administration precipitated sc~erc withdra~al ',.~.mptoms, the dose of llaloxt)ne used hcrc only dcelC~.lsed DA COllcentratJons lo control levels: not to the depressed levels seen during spontaneous w, ithdr,lwal. Second, the time course of naloxone-prccipitalcd withdrav~al symptoms was not correlated with changes in the conccntration of I)A in dialysate. Followhlg naloxonc administration, the withdrawal symptoms ,seen in morphine-dependent rats ranged from their maxinmm during thc first hour, to near minimum during thc hist 3(I min of the test session. Despitc tills marked ,<arialJon in withdrawal symptoms, lllerc was ml Ctlallgc in extracelluhir I)A over thc same pcriod of timc. "l'hcsc dissociations between withdrawal synlptonls and tile concentration of DA in dialysatc suggest ll]at the symptoms of morphine withdrawal ca|mot be caused ,,olcly by variation in the cxtraeelluhir eonccntrali(m ()I" I)t\ hi the vcntral-mcdial striatum.
This conchisJon requires a couple el ca\,¢ats. First.
although our data suggest thai the sYml)loms of nlorphine withdrawal cannel be attributed ~(lJl'] J' [0 abnormally low extracellular eoneenirathms of [)A in the ventral-medial striatum, this does not nle{in that changes in striatal DA neurotransmission play no role in morphine withdrawal. The data onl,, establish that variation in the symptoms associated with morphine withdrawal cannot be explained b.~ \;.iriation in the extracellular concentration of DA ahmc. "l'hcrc may bc a variety of complex presynaptic and postsynaptic adaptations in I)A systems that occur during chronic exposure to morphine, and mteraction~ bctw.ecn various ncuroadaptations in DA systems mab. contribute to the morphine withdrawal syndrome. The nature of such putative interactions, and their relationship to thc morphine withdrawal syndromc, rcrnain to bc determined. Second, the most obviou,', physical signs el withdrawal were quantified in the prcscnt Sltldy. not the avcrsivc subjective experiences thai sonic researchers have proposed may be mcdiatcd by changes in DA neurotransmission [2, 16, 18] . It is always possible, therefore, that there was no dissociation between the subjectiL'e symptoms of withdrawal and extracellular DA concentrations. This would require, however, that in this experiment subjective symptoms were absent when the physical signs of withdrawal were maximal.
In contrast to the decrease in extracellular DA associated with spontaneous morphine withdrawal, there was no change in extracellular DA in the ventral-medial striatum during amphetamine withdrawal. This is consistent with a number of reports of no change in the basal extracellular concentration of DA in the nucleus accumbens over the first 5 days of amphetamine withdrawal [4, 19, 22] ; but seems inconsistent with Rossetti et al. [16] , who reported a significant decrease in extracellular DA in the ventral striatum for 5 days following the discontinuation of chronic amphetamine treatment.
It is not clear what accounts for the discrepancy between the present study (and also [4, 19, 22] ), and that of Rossetti et al. [16] . Our previous study of amphetamine withdrawal [4] , in which a quantitative ('no net flux') microdialysis method was used, differed from that of Rossetti et al. [16] in at least three potentially significant ways. First, in our previous study an escalating dose amphetamine pretreatment regimen was used, in which each of six weekly cycles of five successive drug days were followed by two drug-free days. Thus, in this experiment animals experienced withdrawal several times prior to the dialysis test session ([22] as well), whereas, in the Rossetti et al. experiment [16] animals experienced withdrawal for the first time during the dialysis test session. This raises the possibility that the response to the first experience of amphetamine withdrawal may differ from subsequent experiences. In the present experiment, therefore, we used exactly the same pretreatment regimen as Rossetti et al. [16] , thus eliminating this variable. Second, Rossetti et al. [16] reported the amphetamine withdrawal-associated decrease in DA was maximal the first day following the discontinuation of amphetamine pretreatment, but in the other studies cited above animals were tested between three and five days of withdrawal. Although symptoms of amphetamine withdrawal persist for up to 7 days following the discontinuation of escalating dose amphetamine treatment [9, 11] , animals in the present study were examined on the first day of withdrawal to maximize the probability of detecting a withdrawal-relatcd decreasc in DA concentrations. Third, in the Rossetti et al.
[16] experiment animals received anesthesia the day prior to the dialysis experiment, and in the other studies they did not. This raises the possibility that the decrease in extracellular DA reported by Rossetti ct al.
[16] was due to an interaction between residual effects of anesthesia and amphetamine withdrawal. To test this possibility in the present study, half the animals received anesthesia the day prior to the dialysis test session and half did not. Prior anesthesia had no effect on extracellular DA in the ventral-medial striatum. In conclusion, these three variables do not seem to account for the decrease in extracellular DA reported by Rossetti et al. [16] .
Two other possibilities deserve mention. One, different style microdialysis probes were used in different studies. Rossetti et al. [16] used transverse probes, and concentric vertical probes were used in the present experiment, and by others [4, 19, 22] . The implantation of a transverse probe requires a major surgical procedure the day before the dialysis test session. It is possible, therefore, that the decrease in DA observed by Rossetti et al. [16] was not due to amphetamine withdrawal alone, but to an interaction between the discomfort associated with recent surgical trauma and that associated with amphetamine withdrawal. A second possibility is that transverse probes sample a different portion of the ventral striatum than the concentric probes used here and by others [4, 19, 22] , and the effect of amphetamine withdrawal on extracellular DA is regionally spccific. Consistent with this hypothesis, we found recently that withdrawal from escalating dose amphetamine treatment is associated with a transient decrease in extracellular DA in the dorsolateral caudate nucleus, but not the nucleus accumbens (P. Paulson and T. Robinson, unpublished observations), suggesting there are indeed regional differences in the effects of amphetamine withdrawal on DA neurotransmission.
In summary, under some experimental conditions there may be an association between the extracellular concentration of DA in the ventral striatum and amphetamine or morphine withdrawal, but the data presented here suggest this correlation probably is not due to a necessary, causal relationship. First, during morphine withdrawal it was possible to dissociate variation in the symptoms of withdrawal from variation in extracellular DA concentrations. Second, amphetamine withdrawal was not associated with any change in the concentration of extracellular DA in the ventral-medial striatum. Although the present study does not rule out the possibility that other, more complex, changes in DA neurotransmission play a role in drug withdrawal syndromes, it does suggest that a simple decrease in extracellular DA in the ventral-medial striatum is not a common feature of drug withdrawal syndromes, and does not play a simple causal role in producing thc symptoms of opiate withdrawal.
